| Synonym |
| Thai / English name |
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound :Type of experiment : humanType of animal : -Type of study : non specifiedN(Total) : -N(Treatment) : -Sex : -Age : -Route : Non-specifiedDose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : OmeprazoleDose/Conc.(drug) : -Result : PositiveRemark : Most reports unconfirmed. No effect on CYP1A2, CYP3A4, CYP2E1, CYP2D6 activity in humans, but moderate inducer of CYP2C19. Interaction reported with omeprazole in Chinese patients and fatal seizures in a patient on antieplilepsy medication. Caution if taken with warfarin, antiplatelet dugs, alprazolam, donezepil, trazodone, anticancer drugs.Note : Data from review, data incomplete.
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : Ginkgolide B (GB)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : IntravenousDose/Conc.(herb) : 10 mg/kgDuration : -Type of interaction : PharmacokineticsInteraction with drug : Probenecid*/BenemidDose/Conc.(drug) : 300 mg/kgResult : PositiveRemark : The systemic exposure in the group treated with probenecid (p<0.05 vs control) was significantly raised to 14.75+/-1.328 microgram/mL/h. Specifically, probenecid could significantly decreased the CLtotal of GB from 1.17+/-0.331 to 0.596+/-0.0573 L/h/kg. Albeit probenecid could significantly reduce GB clearance and volume of distribution (V) when compared with control group, the elimination half-time (t1/2lambda) of each group remained close to each other, fitted as 2.04+/-0.376, and 2.34+/-0.851, for the control and probenecid, respectively.Note : CLtotal = total plasma clearance
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : 60% AcetoneType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 53 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : TrifluroperazineDose/Conc.(drug) : 60 micromolarResult : PositiveRemark : Results: Gingko extract inhibited trifluoperazine glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 268.2+/-48.9 microgram/ml. For a RDI 240 mg, this would result in VDI of 0.9 l/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : 60% AcetoneType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 5.3 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : TrifluroperazineDose/Conc.(drug) : 60 micromolarResult : PositiveRemark : Results: Gingko extract inhibited trifluoperazine glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 268.2+/-48.9 microgram/ml. For a RDI 240 mg, this would result in VDI of 0.9 l/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : 60% AcetoneType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 0.53 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : TrifluroperazineDose/Conc.(drug) : 60 micromolarResult : PositiveRemark : Results: Gingko extract inhibited trifluoperazine glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 268.2+/-48.9 microgram/ml. For a RDI 240 mg, this would result in VDI of 0.9 l/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : 60% AcetoneType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 53 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : Serotonin*/5-hydroxytryptamine/5-HTDose/Conc.(drug) : 8 mMResult : NegativeRemark : Results: Data points did not fit the IC50 curve.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : 60% AcetoneType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 5.3 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : Serotonin*/5-hydroxytryptamine/5-HTDose/Conc.(drug) : 8 mMResult : NegativeRemark : Results: Data points did not fit the IC50 curve.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : 60% AcetoneType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 0.53 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : Serotonin*/5-hydroxytryptamine/5-HTDose/Conc.(drug) : 8 mMResult : NegativeRemark : Results: Data points did not fit the IC50 curve.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : 60% AcetoneType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 53 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : Mycophenolic acid*/Mycophenolate/MMF/MPA/MofetilDose/Conc.(drug) : 240 micromolarResult : PositiveRemark : Results: Gingko and acid-hydrolyzed gingko extracts inhibited mycophenolic acid beta-D- glucoronide formation in human liver microsome with IC50 values of 84.3+/-11.6 and 20.9+/-3.6 microgram/ml, respectively. For a RDI of 240 mg, this would result in VDI of 2.9 and 11.4 l/dose for unhydrolyzed and acid hydrolyzed gingko extracts, respectively.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : 60% AcetoneType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 5.3 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : Mycophenolic acid*/Mycophenolate/MMF/MPA/MofetilDose/Conc.(drug) : 240 micromolarResult : PositiveRemark : Results: Gingko and acid-hydrolyzed gingko extracts inhibited mycophenolic acid beta-D- glucoronide formation in human liver microsome with IC50 values of 84.3+/-11.6 and 20.9+/-3.6 microgram/ml, respectively. For a RDI of 240 mg, this would result in VDI of 2.9 and 11.4 l/dose for unhydrolyzed and acid hydrolyzed gingko extracts, respectively.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
